testosterone
Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
---|---|---|---|---|---|---|
Tlando | CAPSULE, ORAL | 112.5 mg | ||||
Jatenzo | CAPSULE, ORAL | 158 mg, 198 mg, 237 mg | ||||
Striant | FILM, EXTENDED RELEASE, BUCCAL | 30 mg/12 hr | ||||
Androderm | FILM, EXTENDED RELEASE, TRANSDERMAL | 2 mg/24 hrs, 4 mg/24 hrs | ||||
Androderm | FILM, EXTENDED RELEASE, TRANSDERMAL | 2.5 mg/24 hrs, 5 mg/24 hrs | ||||
Natesto | GEL, NASAL | 5.5 mg/actuation | ||||
Fortesta | GEL, TRANSDERMAL | 10 mg/0.5 g | ||||
Vogelxo | GEL, TRANSDERMAL | 12.5 g/actuation (1%) | ||||
AndroGel Pump | GEL, TRANSDERMAL | 20.25 mg/actuation (1.62%) | ||||
AndroGel | GEL, TRANSDERMAL | 25 mg/2.5 g (1%), 50 mg/5 g (1%) | ||||
Testim, Vogelxo | GEL, TRANSDERMAL | 50 mg/5 g (1%) | ||||
Aveed | SOLUTION, INTRAMUSCULAR | undecylate 250 mg/mL | ||||
Delatestryl | SOLUTION, INTRAMUSCULAR | enanthate 200 mg/mL | ||||
Depo-Testosterone | SOLUTION, INTRAMUSCULAR | cypionate 200 mg/mL | ||||
Xyosted | SOLUTION, SUBCUTANEOUS | 50 mg/0.5 mL, 75 mg/0.5 mL, 100 mg/0.5 mL | ||||
Axiron | SOLUTION, TRANSDERMAL | 30 mg/1.5 mL |
ORDERED FORMULATION
THERAPEUTIC INTERCHANGE
testosterone (Androderm)
testosterone (Androderm)
*All strengths of ANDRODERM patch (2 mg, 2.5 mg, 4 mg, 5 mg) have been removed from the market as of March 2023.
testosterone (AndroGel Pump)
testosterone (AndroGel)
ONE 25 mg/2.5 g packet once Daily (Total: 75 mg)
Give at same dosing interval
testosterone (Axiron)
testosterone (AndroGel)
testosterone (Fortesta)
testosterone (AndroGel)
testosterone (Natesto)
testosterone (AndroGel)
testosterone (Testim, Vogelxo)
testosterone (AndroGel)
Intercahnge on 1 mg: 1 mg testosterone ratio
testosterone (Vogelxo pump)
testosterone (AndroGEL)
ANDRODERM patches have been discontinued. *Recommend 1% transdermal gel to prescriber. (No automatic interchange as of May 2023)
AVEED is classified as non-formulary, not stocked.
Striant is approved for formulary status, not generally stocked. Usage is expected to be extremely low.
Delatestryl : available as an intramuscular (IM) oil, is currently on formulary.
Xyosted : Non-formulary, not stocked and inpatients should use their home supply. Initation of Xyosted should be deferred to the outpatient home setting.
DETERRA INFORMATION:
Deterra drug deactivation system is to be used for the disposal of testosterone patches. When a patch is placed inside the pouch and water is added the drug is deactivated. The sealed pouch is then discarded in the regular trash. The Deterra pouch is removed from pyxis by the nurse under the patient's name with a witness.
Deterra Drug Deactivation Pouch Disposal
Deterra Drug Deactivation Pyxis Removal
Jatenzo & Tlando: Inpatients may use home supply. Recommend alternative products (buccal or transdermal) if prescribed and/or home supply is unavailable.
Reviewed: February 28, 2006 (Striant) and April 26, 2011 (AXIRON and FORTESTA) and January 24, 2012 (ANDRODERM patch strengths) and December 16, 2014 (Aveed) and 24 February 2015 (Natesto and Vogelxo) and 23 July 2019 (Xyosted), August 2023 (Jatenzo), Sept 2023 (Tlando)
Androgel 1% medication guide
Androgel 1.62% medication guide
Aveed medication guide
Axiron medication guide
Fortesta medication guide
Testim medication guide
testosterone gel medication guide
Vogelxo medication guide